⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer

Official Title: Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer

Study ID: NCT01840306

Interventions

Biomarker Analysis

Study Description

Brief Summary: Primary Objective: (i) To identify panels of RNAs and proteins predictive of response to HER2 targeted agents, considering clinical responses. (ii) To investigate associations between presence vs. absence (or relative levels) of identified extracellular (EC) RNAs/proteins and patients' clinicopathological characteristics, including age at diagnosis, time to progression and overall survival, as well as correlations with serum protein biomarkers routinely analysed for these patients. (iii) To compare HER2 positive samples versus HER2 negative samples for the existence of RNAs/proteins identified in (i) and (ii). Secondary Objective: To develop a predictive model for use in the HER2 positive population based on the most accurate and sensitive combination of the identified biomarkers.

Detailed Description: This is a translational pilot study, involving two patient cohorts, designed to identify predictive biomarkers for HER2 targeted therapy, which will be validated in a larger future study. Cohort 1: 300 newly diagnosed (including metastatic) HER2 positive breast cancer patients. Cohort 2: 30 newly diagnosed HER2 negative breast cancer patients. Blood specimens will be taken: * before starting treatment (cohort 1 and 2) * after receiving chemotherapy and before starting HER2 targeted treatment (if applicable) (cohort 1) * within one month following 1st treatment of HER2 targeted treatment (cohort 1) * approximately every 3 months (coinciding with formal disease assessment) while on HER2 targeted treatment for a maximum of 5 years (cohort 1) Blood will be processed to serum, which will be analysed for RNA and protein biomarkers.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

Bon Secours Hospital, Cork, , Ireland

Cork University Hospital, Cork, , Ireland

Letterkenny General Hospital, Donegal, , Ireland

Our Lady of Lourdes Hospital, Drogheda, , Ireland

Beacon Hospital, Dublin, , Ireland

Beaumont Hospital, Dublin, , Ireland

St James's Hospital, Dublin, , Ireland

St Vincent's University Hospital, Dublin, , Ireland

The Adelaide & Meath Hospital, Dublin Incorporating the National Children's Hospital, Dublin, , Ireland

Sligo General Hospital, Sligo, , Ireland

University Hospital Waterford, Waterford, , Ireland

Contact Details

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: